Amgen vet Laura Hamill takes commercial reins at Gilead amid executive shakeup
In the latest move in a reshuffle of senior execs among the biggest players in biopharma, Gilead has tapped longtime Amgen vet Laura Hamill to head its commercial team.
Hamill fills a position vacated by the retirement of James Meyers, whose career trajectory was quite similar to hers: He joined Gilead in 1996 as a regional sales director, climbing all the way up to EVP, commercial operations. Hamill had been with Amgen since 2002, most recently serving as SVP, US business operations.
Her new role gives her broad authority over Gilead’s marketing strategy and product launches around the world.
“Over the past several months, we have conducted an extensive search for a new leader and we believe that Laura brings to Gilead the kind of operational rigor and organizational experience that will help us as we seek to build on our position of strength in existing therapeutic areas and introduce products in new ones,” said John Milligan, president and CEO of Gilead. “She has repeatedly demonstrated an ability to transform infrastructure and capabilities to drive innovation and business performance.
Hamill joins Gilead at a time the big biotech is undergoing a major soul searching amidst a C-suite exodus. CEO Milligan and chairman John Martin, who together made biotech history by developing a painless hepatitis C cure and building a giant in the HIV space, are both stepping down at the end of the year. R&D chief Norbert Bischofberger — who spent 30 years with the company — left for a startup in May; Andrew Cheng, newly appointed chief medical officer in the wake of Bischofberger’s departure, handed in his own notice days ago.
Hamill’s move also comes a day after Bristol-Myers Squibb announced it has promoted Christopher Boerner to its top sales job, replacing Murdo Gordon, who recently jumped ship to become commercial chief at Amgen.